Exosome therapy: strong biology, limited human evidence

Exosomes are small membrane-bound vesicles released by almost every cell type in the body. They carry proteins, lipids and RNA between cells, and for roughly two decades they have been studied as a mechanism by which cells communicate — including, potentially, how stem cells exert effects on tissue they never physically contact.

Why the interest

Much of the enthusiasm comes from a reinterpretation of stem cell therapy. Early assumptions held that transplanted cells worked by engrafting and replacing damaged tissue. Later work suggested that in many cases they do not persist long enough for that to be the mechanism, and that much of their effect may be paracrine — mediated by what the cells secrete rather than by the cells themselves.

If that is correct, the secreted fraction becomes interesting on its own. It would be easier to store, easier to standardise, and would avoid the risks that come with administering living cells. That is a reasonable hypothesis, and it is why the field exists.

What the evidence currently supports

Preclinical work is extensive. Exosome preparations have shown effects on wound healing, cardiac injury, kidney injury and inflammatory conditions in animal models, and the mechanistic literature on vesicle biology is substantial and credible.

Human data is much thinner. Published clinical experience consists largely of small series and case reports, the best known being a compassionate-use case of MSC-derived exosomes in treatment-refractory graft-versus-host disease. [1]

Registered trials are underway across a range of indications, but few have reported controlled outcome data. Anyone describing exosome therapy as clinically proven for orthopaedic, aesthetic or anti-aging use is ahead of the published evidence.

The characterisation problem

A practical difficulty runs underneath all of this. What one supplier sells as exosomes and what another sells may differ substantially in vesicle size, purity, cell source, isolation method and dose. The International Society for Extracellular Vesicles publishes minimal reporting standards precisely because of this variability. [2]

The consequence is that results from one product do not transfer to another, and that a clinic offering exosome therapy may be administering something quite different from whatever was used in the study they cite.

Regulatory status

In the United States, exosome products are not approved for any indication. The FDA has issued public warnings about unapproved exosome products, including following reports of serious adverse events in patients who received them at clinics. [3]

Questions worth asking

For patients considering exosome therapy, and for physicians fielding the question, a few points separate a considered offering from a marketing one: what the cell source is, how the product was isolated and characterised, what dose is being given and on what basis, whether the provider can point to human outcome data for that specific product, and what the plan is if there is an adverse reaction.

None of these are unreasonable questions, and a provider who cannot answer them is not in a position to be administering the product.

Where this leaves the field

Exosome biology is genuine science with plausible therapeutic potential, and it would not be surprising if approved products eventually emerge. What does not yet exist is the controlled human evidence that would justify the claims currently made in the direct-to-consumer market. Those two statements are both true, and holding them together is the honest position.